Aducanumab Fall-Out: An Inexpedient Use Of ‘Expedited’ Review

 
• By Michael McCaughan
  
Express delivery van jumps over cliff
The US FDA chose the most direct route to deliver the Biogen Alzheimer’s candidate to market, but it might not make it. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers